Chimerix Priced, Nasdaq: CMRX
Developing a potent antiviral drug for use in stem cell transplants.
Industry: Health Care
First Day Return: +34.2%
CMRX
Developing a potent antiviral drug for use in stem cell transplants.
| IPO Data | |
|---|---|
| IPO Date | 04/10/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $102 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Durham, NC, United States |
| Founded | 2000 |
| Employees at IPO | 46 |
| Website www.chimerix.com | |
IPO News for Chimerix
Chimerix (CMRX) Performance
